Manager TitleAgeSince
President - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 75 2011-07-27
Director/Board Member 63 2017-10-31
Director/Board Member 66 2018-01-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 711M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.27%-2.95%+30.65%+247.47% 30.05B
Weighted average by Cap. -0.55%-2.83%+31.25%+170.65%
Logo Peloton Therapeutics, Inc.
Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company's product pipeline includes Hypoxia-inducible factor-2? (HIF-2?). HIF-2? is a transcription factor that, in part, regulates the body's response to diminished availability of oxygen. The Company's lead drug candidate, PT2977, is an oral HIF-2?. The Company is focused on developing PT2977 for the treatment of kidney cancer, specifically metastatic clear cell renal cell carcinoma (mRCC) and von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). HIF-2? is aberrantly activated in these diseases as a result of the inactivity of the VHL tumor suppressor. The Company is also developing PT2567, an oral HIF-2? inhibitor, for non-oncology indications.
Employees
64
  1. Stock Market
  2. Stocks
  3. PLTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!